Please login to the form below

Not currently logged in
Email:
Password:

paliperidone

This page shows the latest paliperidone news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson &Johnson’s Invega Sustenna (paliperidone) but, for now, Indivior

Latest news

  • Allergan and Gedeon finally get antipsychotic green light Allergan and Gedeon finally get antipsychotic green light

    Once-monthly examples include Otsuka/Lundbeck's Abilify Maintena (aripiprazole) and Johnson and Johnson's Invega Sustenna (paliperidone palmitate), while J&J is also developing a three-monthly paliperidone depot that

  • J&J files three-monthly schizophrenia drug in Europe J&J files three-monthly schizophrenia drug in Europe

    Johnson &Johnson has submitted a new depot formulation of its antipsychotic therapy paliperidone in Europe, shortly after the new version was approved in the US. ... J&J sells a once-monthly version of paliperidone as Invega Sustenna in the US and

  • More waiting for Allergan and Gedeon Richter's antipsychotic More waiting for Allergan and Gedeon Richter's antipsychotic

    The drug is one of several new antipsychotic agents expected to drive growth in the schizophrenia market in the coming years, along with Johnson &Johnson's three-monthly paliperidone palmitate depot,

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Before patients can be started on the drug they must first be taking Janssen's Invega Sustenna, a one-month form of paliperidone palmitate,

  • J&J gets quicker review for schizophrenia depot in US J&J gets quicker review for schizophrenia depot in US

    The US FDA has granted priority review status to Johnson &Johnson's paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times ... The current formulation of paliperidone - sold as

More from news
Approximately 3 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics